Skip to Main Content

Sarepta Therapeutics CEO Doug Ingram is taking the high road.

In remarks Thursday on a quarterly earnings call, Ingram refused to criticize the Food and Drug Administration for rejecting Sarepta’s Duchenne muscular dystrophy drug Vyondys 53.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.